Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results
23 Mars 2023 - 10:00PM
Daix (France),
Long Island City (New York, United
States), March
23, 2023 – Inventiva (Euronext
Paris and Nasdaq: IVA) (the “Company”), a clinical-stage
biopharmaceutical company focused on the development of oral small
molecule therapies for the treatment of patients with non-alcoholic
steatohepatitis (NASH) and other diseases with significant unmet
medical needs, today announced that its management team will host a
webcast to present the Company’s 2022 full-year financial results
on Thursday, March 30, 2023.
Inventiva’s 2022
full-year financial results will be published on Wednesday, March
29, 2023 at 4:00 pm (New York), 10:00 pm (Paris).
Frédéric Cren, Chairman, CEO and cofounder of
Inventiva, Pierre Broqua, Chief Scientific Officer and cofounder of
Inventiva, Jean Volatier, Chief Financial Officer of Inventiva, and
Michael Cooreman, Chief Medical Officer of Inventiva, will hold a
conference call in English, followed by a Q&A
session, on
Thursday, March 30,
2023, at 8:00 am
(New York),
2:00 pm
(Paris).
The conference call and the slides of the
presentation will be webcast live at:
https://edge.media-server.com/mmc/p/jdzcm24d and also available on
Inventiva’s onwards in the “Investors” – “Financial results”
section.
In order to receive the conference
access information necessary to join the
conference call, it
is required to
register in advance using the following link:
https://register.vevent.com/register/BI64f8e310179a49e2a675a18f401f7241.
In the 10 minutes prior to the call start time,
participants will need to use the conference access information
provided in the e-mail received at the point of registering
(dial-in number and access code).
A replay of the conference call and the
presentation will be available after the event at:
http://inventivapharma.com/investors/financial-results-presentations/.About
Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the research and development of oral small
molecule therapies for the treatment of patients with NASH,
mucopolysaccharidoses (“MPS”) and other diseases with significant
unmet medical need. The Company benefits from a strong expertise
and experience in the domain of compounds targeting nuclear
receptors, transcription factors and epigenetic modulation.
Inventiva is currently advancing one clinical candidate, has a
pipeline of two preclinical programs and continues to explore other
development opportunities to add to its pipeline.
Inventiva’s lead product candidate,
lanifibranor, is currently in a pivotal Phase III clinical trial,
NATiV3, for the treatment of adult patients with NASH, a common and
progressive chronic liver disease for which there are currently no
approved therapies.
Inventiva’s pipeline also includes odiparcil, a
drug candidate for the treatment of adult MPS VI patients. As part
of Inventiva’s decision to focus clinical efforts on the
development of lanifibranor, it suspended its clinical efforts
relating to odiparcil and is reviewing available options with
respect to its potential further development. Inventiva is also in
the process of selecting an oncology development candidate for its
Hippo signaling pathway program.
The Company has a scientific team of
approximately 80 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, and clinical development. It owns an extensive
library of approximately 240,000 pharmacologically relevant
molecules, approximately 60% of which are proprietary, as well as a
wholly-owned research and development facility.
Inventiva is a public company listed on
compartment C of the regulated market of Euronext Paris (ticker:
IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com
Contacts
InventivaPascaline ClercVP of Global External
Affairsmedia@inventivapharma.com+1 240 620 9175 |
Brunswick GroupTristan Roquet Montegon / Aude
LepreuxMatthieu BenoistMedia
relationsinventiva@brunswickgroup.com+33 1 53 96 83 83 |
Westwicke,
an ICR CompanyPatricia L. BankInvestor
relationspatti.bank@westwicke.com+1 415 513 1284 |
|
|
|
- Inventiva - PR - Webcast invitation FY 2022 - EN -
17.03.2023
Inventiva (EU:IVA)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Inventiva (EU:IVA)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024